US1027347A
(en)
|
1910-11-23 |
1912-05-21 |
Columbus K Lassiter |
Multiple-spindle drill.
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
US4880635B1
(en)
|
1984-08-08 |
1996-07-02 |
Liposome Company |
Dehydrated liposomes
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US4921757A
(en)
|
1985-04-26 |
1990-05-01 |
Massachusetts Institute Of Technology |
System for delayed and pulsed release of biologically active substances
|
US4920016A
(en)
|
1986-12-24 |
1990-04-24 |
Linear Technology, Inc. |
Liposomes with enhanced circulation time
|
JPH0825869B2
(ja)
|
1987-02-09 |
1996-03-13 |
株式会社ビタミン研究所 |
抗腫瘍剤包埋リポソ−ム製剤
|
US4911928A
(en)
|
1987-03-13 |
1990-03-27 |
Micro-Pak, Inc. |
Paucilamellar lipid vesicles
|
US4917951A
(en)
|
1987-07-28 |
1990-04-17 |
Micro-Pak, Inc. |
Lipid vesicles formed of surfactants and steroids
|
ATE113059T1
(de)
|
1987-06-24 |
1994-11-15 |
Florey Howard Inst |
Nukleosid-derivate.
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5859221A
(en)
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
US5457191A
(en)
|
1990-01-11 |
1995-10-10 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5587470A
(en)
|
1990-01-11 |
1996-12-24 |
Isis Pharmaceuticals, Inc. |
3-deazapurines
|
US5149797A
(en)
|
1990-02-15 |
1992-09-22 |
The Worcester Foundation For Experimental Biology |
Method of site-specific alteration of rna and production of encoded polypeptides
|
ATE154246T1
(de)
|
1990-07-27 |
1997-06-15 |
Isis Pharmaceuticals Inc |
Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
US6582908B2
(en)
|
1990-12-06 |
2003-06-24 |
Affymetrix, Inc. |
Oligonucleotides
|
US5948903A
(en)
|
1991-01-11 |
1999-09-07 |
Isis Pharmaceuticals, Inc. |
Synthesis of 3-deazapurines
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
ATE226093T1
(de)
|
1991-11-26 |
2002-11-15 |
Isis Pharmaceuticals Inc |
Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
US20040054156A1
(en)
|
1992-05-14 |
2004-03-18 |
Kenneth Draper |
Method and reagent for inhibiting hepatitis B viral replication
|
US5434257A
(en)
|
1992-06-01 |
1995-07-18 |
Gilead Sciences, Inc. |
Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
|
JPH08504559A
(ja)
|
1992-12-14 |
1996-05-14 |
ハネウエル・インコーポレーテッド |
個別に制御される冗長巻線を有するモータシステム
|
KR940021073A
(ko)
|
1993-03-02 |
1994-10-17 |
미야베 요시가즈 |
알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
|
JPH06329551A
(ja)
*
|
1993-03-22 |
1994-11-29 |
Mitsubishi Kasei Corp |
アルツハイマー病の予防または治療薬およびそのスクリーニング方法
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
US5801154A
(en)
|
1993-10-18 |
1998-09-01 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of multidrug resistance-associated protein
|
GB9323483D0
(en)
|
1993-11-13 |
1994-01-05 |
Cerestar Holding Bv |
Edible composition and a process for its preparation
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
USRE44779E1
(en)
|
1997-03-07 |
2014-02-25 |
Santaris Pharma A/S |
Bicyclonucleoside and oligonucleotide analogues
|
US6770748B2
(en)
|
1997-03-07 |
2004-08-03 |
Takeshi Imanishi |
Bicyclonucleoside and oligonucleotide analogue
|
JP3756313B2
(ja)
|
1997-03-07 |
2006-03-15 |
武 今西 |
新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
|
US6617162B2
(en)
*
|
2001-12-18 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of estrogen receptor alpha expression
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
EP2253639A1
(en)
|
1997-09-12 |
2010-11-24 |
Exiqon A/S |
Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
|
US5942275A
(en)
|
1997-10-27 |
1999-08-24 |
The Procter & Gamble Company |
Flavored nut spreads having milk chocolate flavor and creamy soft texture
|
US20030228597A1
(en)
|
1998-04-13 |
2003-12-11 |
Cowsert Lex M. |
Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
|
AU4322999A
(en)
|
1998-06-01 |
1999-12-20 |
Advanced Research And Technology Institute, Inc. |
Methods and compositions for diagnosing tauopathies
|
ID30093A
(id)
*
|
1999-02-12 |
2001-11-01 |
Sankyo Co |
Analog-analog nukleosida dan oligonukleotida baru
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
AU781598B2
(en)
|
1999-04-21 |
2005-06-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibiting the function of polynucleotide sequences
|
EP1178999B1
(en)
|
1999-05-04 |
2007-03-14 |
Santaris Pharma A/S |
L-ribo-lna analogues
|
US6525191B1
(en)
|
1999-05-11 |
2003-02-25 |
Kanda S. Ramasamy |
Conformationally constrained L-nucleosides
|
JP4151751B2
(ja)
|
1999-07-22 |
2008-09-17 |
第一三共株式会社 |
新規ビシクロヌクレオシド類縁体
|
EP1097941A1
(en)
|
1999-11-05 |
2001-05-09 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies
|
ATE353663T1
(de)
*
|
1999-12-08 |
2007-03-15 |
Cyclacel Pharmaceuticals Inc |
Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten
|
JP2004509604A
(ja)
|
2000-03-28 |
2004-04-02 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
mRNAプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
|
AU2001250572A1
(en)
|
2000-04-07 |
2001-10-23 |
Epigenomics Ag |
Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
|
JP2004532022A
(ja)
|
2001-03-26 |
2004-10-21 |
サーナ・セラピューティクス・インコーポレイテッド |
B型肝炎ウイルスおよびc型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
|
US20050019915A1
(en)
|
2001-06-21 |
2005-01-27 |
Bennett C. Frank |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
US20030175906A1
(en)
|
2001-07-03 |
2003-09-18 |
Muthiah Manoharan |
Nuclease resistant chimeric oligonucleotides
|
WO2003004602A2
(en)
|
2001-07-03 |
2003-01-16 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
AU2002365157A1
(en)
|
2001-11-08 |
2003-07-15 |
The Johns Hopkins University |
Methods and systems of nucleic acid sequencing
|
US20070203333A1
(en)
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050153336A1
(en)
*
|
2002-03-29 |
2005-07-14 |
Bennett C. F. |
Compositions and their uses directed to nucleic acid binding proteins
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
US20040110149A1
(en)
*
|
2002-12-10 |
2004-06-10 |
Isis Pharmaceuticals Inc. |
Modulation of BUB1-beta expression
|
AU2003268032A1
(en)
|
2002-07-29 |
2004-02-16 |
Epigenesis Pharmaceuticals, Inc. |
Composition and methods for treatment and screening
|
US20040241854A1
(en)
|
2002-08-05 |
2004-12-02 |
Davidson Beverly L. |
siRNA-mediated gene silencing
|
US20050106731A1
(en)
|
2002-08-05 |
2005-05-19 |
Davidson Beverly L. |
siRNA-mediated gene silencing with viral vectors
|
WO2004017072A1
(en)
*
|
2002-08-14 |
2004-02-26 |
Universität Zürich |
A cellular assay system for neurofibrillary tangle formation
|
US20060035344A1
(en)
|
2002-10-18 |
2006-02-16 |
Pachuk Catherine J |
Double-stranded rna structures and constructs, and methods for generating and using the same
|
AU2003291753B2
(en)
|
2002-11-05 |
2010-07-08 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
AU2003291755A1
(en)
|
2002-11-05 |
2004-06-07 |
Isis Pharmaceuticals, Inc. |
Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
|
ATE517992T1
(de)
|
2002-11-14 |
2011-08-15 |
Dharmacon Inc |
Funktionelle und hyperfunktionelle sirna
|
US20080318210A1
(en)
|
2003-08-27 |
2008-12-25 |
Rosetta Genomics |
Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
|
JP2004187609A
(ja)
*
|
2002-12-12 |
2004-07-08 |
Sankyo Co Ltd |
最適アンチセンス配列の決定法
|
US6673661B1
(en)
|
2002-12-20 |
2004-01-06 |
Taiwan Semiconductor Manufacturing Co., Ltd. |
Self-aligned method for forming dual gate thin film transistor (TFT) device
|
WO2004106356A1
(en)
|
2003-05-27 |
2004-12-09 |
Syddansk Universitet |
Functionalized nucleotide derivatives
|
AU2003904328A0
(en)
|
2003-08-13 |
2003-08-28 |
Garvan Institute Of Medical Research |
Diagnosis and treatment of neurodegenerative disorders
|
US7427672B2
(en)
|
2003-08-28 |
2008-09-23 |
Takeshi Imanishi |
Artificial nucleic acids of n-o bond crosslinkage type
|
AU2004274021B2
(en)
|
2003-09-18 |
2009-08-13 |
Isis Pharmaceuticals, Inc. |
4'-thionucleosides and oligomeric compounds
|
WO2005030928A2
(en)
|
2003-09-23 |
2005-04-07 |
Chihiro Koike |
PORCINE INVARIANT CHAIN PROTEIN, FULL LENGTH cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
|
US20050244851A1
(en)
|
2004-01-13 |
2005-11-03 |
Affymetrix, Inc. |
Methods of analysis of alternative splicing in human
|
CN100410383C
(zh)
|
2004-05-11 |
2008-08-13 |
中国农业科学院生物技术研究所 |
一种昆虫杆状病毒生物反应器的制备方法
|
EP1752536A4
(en)
|
2004-05-11 |
2008-04-16 |
Alphagen Co Ltd |
POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
|
ES2415665T3
(es)
|
2004-06-21 |
2013-07-26 |
Proteome Sciences Plc |
Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
|
US7964346B2
(en)
*
|
2004-10-27 |
2011-06-21 |
Rubin Donald H |
Mammalian genes involved in infection
|
US20080003570A1
(en)
|
2004-12-22 |
2008-01-03 |
The General Hospital Corporation |
Translation enhancer elements of genes encoding human Tau protein and human alpha-synuclein protein
|
US20060216722A1
(en)
|
2005-03-25 |
2006-09-28 |
Christer Betsholtz |
Glomerular expression profiling
|
US20090176725A1
(en)
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
JP5523705B2
(ja)
|
2005-08-29 |
2014-06-18 |
レグルス・セラピューティクス・インコーポレイテッド |
Mir−122aをモジュレートする使用方法
|
ATE529441T1
(de)
|
2005-08-30 |
2011-11-15 |
Novo Nordisk As |
Expression von proteinen in e.coli
|
RU2448974C2
(ru)
*
|
2005-11-01 |
2012-04-27 |
Элнилэм Фармасьютикалз, Инк. |
РНКи-ИНГИБИРОВАНИЕ РЕПЛИКАЦИИ ВИРУСА ГРИППА
|
US7569686B1
(en)
|
2006-01-27 |
2009-08-04 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for synthesis of bicyclic nucleic acid analogs
|
AU2007211080B9
(en)
|
2006-01-27 |
2012-05-03 |
Isis Pharmaceuticals, Inc. |
6-modified bicyclic nucleic acid analogs
|
US8178503B2
(en)
|
2006-03-03 |
2012-05-15 |
International Business Machines Corporation |
Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
|
GB0605337D0
(en)
|
2006-03-17 |
2006-04-26 |
Genomica Sau |
Treatment of CNS conditions
|
ES2386578T3
(es)
|
2006-05-05 |
2012-08-23 |
Isis Pharmaceuticals, Inc. |
Compuestos y procedimientos para modular la expresión de PCSK9
|
ES2389737T3
(es)
|
2006-05-11 |
2012-10-31 |
Isis Pharmaceuticals, Inc. |
Análogos de ácidos nucleicos bicíclicos modificados en 5'
|
US7666854B2
(en)
|
2006-05-11 |
2010-02-23 |
Isis Pharmaceuticals, Inc. |
Bis-modified bicyclic nucleic acid analogs
|
CA2666185A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Influenza targets
|
JP2010507387A
(ja)
*
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のsiRNAおよびその使用方法
|
US20100190837A1
(en)
|
2007-02-15 |
2010-07-29 |
Isis Pharmaceuticals, Inc. |
5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
|
WO2008124066A1
(en)
|
2007-04-05 |
2008-10-16 |
The J. David Gladstone Institutes |
Agents that reduce neuronal overexcitation
|
KR101738655B1
(ko)
|
2007-05-01 |
2017-05-22 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
Tnf 슈퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질병 치료에 있어서의 그의 용도
|
EP2170917B1
(en)
|
2007-05-30 |
2012-06-27 |
Isis Pharmaceuticals, Inc. |
N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
|
EP2173760B2
(en)
|
2007-06-08 |
2015-11-04 |
Isis Pharmaceuticals, Inc. |
Carbocyclic bicyclic nucleic acid analogs
|
WO2008151631A2
(en)
|
2007-06-15 |
2008-12-18 |
Exiqon A/S |
Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
|
DK2176280T4
(en)
|
2007-07-05 |
2015-07-20 |
Isis Pharmaceuticals Inc |
6-Disubstituerede bicykliske nukleinsyreanaloge
|
US8088904B2
(en)
|
2007-08-15 |
2012-01-03 |
Isis Pharmaceuticals, Inc. |
Tetrahydropyran nucleic acid analogs
|
US20090076725A1
(en)
|
2007-09-14 |
2009-03-19 |
Kulvir Singh Bhogal |
Conveyance mode aware navigation device
|
AU2008323970B2
(en)
*
|
2007-11-09 |
2014-05-08 |
Isis Pharmaceuticals, Inc. |
Modulation of Factor 7 expression
|
WO2009067647A1
(en)
|
2007-11-21 |
2009-05-28 |
Isis Pharmaceuticals, Inc. |
Carbocyclic alpha-l-bicyclic nucleic acid analogs
|
EP2265627A2
(en)
|
2008-02-07 |
2010-12-29 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexitol nucleic acid analogs
|
EP2268813A4
(en)
|
2008-04-07 |
2012-10-10 |
Univ Queensland |
RNA MOLECULES AND THEIR USE
|
BRPI0801674B1
(pt)
|
2008-06-04 |
2015-08-18 |
Luiz Carmine Giunti De Oliveira |
Formulação de creme de alfarroba com avelã sem adição de açúcar, sem lactose e sem glúten
|
WO2010036698A1
(en)
|
2008-09-24 |
2010-04-01 |
Isis Pharmaceuticals, Inc. |
Substituted alpha-l-bicyclic nucleosides
|
BRPI0901526A2
(pt)
|
2009-05-19 |
2011-01-18 |
Laerte Casoni José |
formulação de pasta de avelã sem adição de sacarose, enriquecida com fibras
|
HUE046966T2
(hu)
|
2009-06-17 |
2020-04-28 |
Biogen Ma Inc |
Készítmények és módszerek az SMN2 splicing egy alanynál történõ modulálására
|
WO2011005786A2
(en)
|
2009-07-06 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for enhancing production of a biological product
|
CA2767231A1
(en)
|
2009-07-06 |
2011-01-13 |
Alnylam Pharmaceuticals, Inc. |
Cell-based bioprocessing
|
US20110041191A1
(en)
|
2009-07-09 |
2011-02-17 |
Bettina Platt |
Animal model, and products and methods useful for the production thereof
|
WO2011017521A2
(en)
|
2009-08-06 |
2011-02-10 |
Isis Pharmaceuticals, Inc. |
Bicyclic cyclohexose nucleic acid analogs
|
US8791087B2
(en)
|
2009-08-21 |
2014-07-29 |
Curna, Inc. |
Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP
|
KR102173836B1
(ko)
*
|
2009-09-11 |
2020-11-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
헌팅틴 발현의 조절
|
RU2619185C2
(ru)
|
2009-12-23 |
2017-05-12 |
Курна, Инк. |
Лечение заболеваний, связанных с разобщающим белком 2 (ucp2), путем ингибирования природного антисмыслового транскрипта к ucp2
|
US8653047B2
(en)
*
|
2010-01-08 |
2014-02-18 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
EP3561060A1
(en)
|
2010-02-08 |
2019-10-30 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
GB2471149B
(en)
|
2010-03-04 |
2011-06-08 |
Eger Olive Oil Products Industry Ltd Dr |
Olive oil based flavoured spreads
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP3231446A1
(en)
|
2010-04-19 |
2017-10-18 |
Nlife Therapeutics S.L. |
Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
|
WO2011133876A2
(en)
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
WO2012005898A2
(en)
|
2010-06-15 |
2012-01-12 |
Alnylam Pharmaceuticals, Inc. |
Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof
|
WO2012018881A2
(en)
|
2010-08-03 |
2012-02-09 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for the regulation of rna
|
WO2012145582A2
(en)
|
2011-04-22 |
2012-10-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibitions of egfr by double-stranded rna
|
WO2012177639A2
(en)
|
2011-06-22 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Bioprocessing and bioproduction using avian cell lines
|
US8906441B2
(en)
|
2011-09-22 |
2014-12-09 |
Hormel Foods Corporation |
Peanut spread
|
WO2013066721A2
(en)
|
2011-11-04 |
2013-05-10 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of met by double-stranded rna
|
EP2782571A4
(en)
*
|
2011-11-23 |
2015-04-01 |
Intellikine Llc |
HETEROCYCLIC COMPOUNDS AND USES THEREOF
|
BE1020640A3
(nl)
|
2011-12-03 |
2014-02-04 |
Cavalier Nv |
Een met vezels verrijkte vulsamenstelling voor een chocoladeproduct.
|
AU2013203395A1
(en)
|
2012-03-30 |
2013-10-17 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating TAU expression for reducing seizure and modifying a neurodegenerative syndrome
|
JP2015523855A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Apoa1及びabca1発現を調節するための組成物及び方法
|
CN104661664B
(zh)
|
2012-07-13 |
2020-07-03 |
波涛生命科学有限公司 |
手性控制
|
GB201301233D0
(en)
|
2013-01-24 |
2013-03-06 |
Queen Mary & Westfield College |
Method
|
ITGE20130015A1
(it)
|
2013-02-01 |
2014-08-02 |
Microtem Di Mattia Chiodetti E Savi No Larocca Snc |
Dispositivo di tenuta meccanica, in particolare per alberi di trasmissione in navi, natanti o simili
|
KR20150130430A
(ko)
|
2013-03-14 |
2015-11-23 |
아이시스 파마수티컬즈 인코포레이티드 |
타우 발현을 조절하는 조성물 및 방법
|
RU2650510C2
(ru)
|
2013-05-01 |
2018-04-16 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии аполипопротеина c-iii
|
DK3007564T3
(da)
|
2013-06-10 |
2020-03-09 |
Cargill Inc |
Struktureret fedtsystem
|
TW202246503A
(zh)
*
|
2013-07-19 |
2022-12-01 |
美商百健Ma公司 |
用於調節τ蛋白表現之組合物
|
DE102013108693B3
(de)
|
2013-08-12 |
2014-12-24 |
Mars Inc. |
Schale
|
TR201901378T4
(tr)
|
2013-11-15 |
2019-02-21 |
Aak Ab Publ |
Kakao yağı stabilize edici bitkisel katı yağ bileşimi.
|
US10119136B2
(en)
|
2014-01-09 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
RNAi agents modified at the 4′-C position
|
US20170211064A1
(en)
|
2014-07-29 |
2017-07-27 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating tau expression
|
EP3253875B1
(en)
|
2015-02-04 |
2020-01-08 |
H. Hoffnabb-La Roche Ag |
Tau antisense oligomers and uses thereof
|
EP3253871A1
(en)
|
2015-02-04 |
2017-12-13 |
Bristol-Myers Squibb Company |
Lna oligonucleotides with alternating flanks
|
WO2016151523A1
(en)
|
2015-03-25 |
2016-09-29 |
Università Degli Studi Di Trento |
Rna interference mediated therapy for neurodegenerative diseases
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
BR112018006147B1
(pt)
|
2015-09-29 |
2022-06-07 |
Bunge Loders Croklaan B.V. |
Composição de creme de chocolate e/ou de recheio, e, método para preparação de uma composição de creme de chocolate e/ou recheio de confeitaria
|
JOP20200228A1
(ar)
|
2015-12-21 |
2017-06-16 |
Novartis Ag |
تركيبات وطرق لخفض تعبير البروتين tau
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
AR109750A1
(es)
|
2016-09-29 |
2019-01-23 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para reducir la expresión de tau
|